Lupin Strengthens Diabetes Portfolio with USFDA Approval for High-Value Injectables

has received approval from the US Food and Drug Administration for its generic versions of two key diabetes-related injectable products—Liraglutide Injection (18 mg/3 mL) and Glucagon for Injection (1 mg/vial), both of which will be manufactured at its Nagpur facility, reinforcing its capabilities in complex injectables; Liraglutide, a bioequivalent to Novo Nordisk’s Victoza, is used alongside diet and exercise to improve glycemic control in type 2 diabetes patients aged 10 years and above, with an estimated U.S. market size of $458 million, while Glucagon, used for treating severe hypoglycemia, targets an additional $124 million market, taking the combined opportunity to around $582 million, thereby enhancing Lupin’s U.S. portfolio and strengthening its position in the anti-diabetic segment, with management highlighting this as a strategic step to expand access to critical therapies and drive long-term growth in complex generics. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.